RARiad Mohammed Abdelrahman

Riad Mohammed Abdelrahman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Riad Mohammed Abdelrahman has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Global Trends in Guideline-Directed Medical Therapy for Patients With Heart Failure: A Bibliometric and Thematic Analysis of Articles Indexed in Scopus (2013-2025)

    by Mohsen Hussein Suliman, Magdi Awad Yousef Sasi, Abdalla Omer Elkhawad, Riad Mohammed Abdelrahman, Kannan O. Ahmed

    Heart Failure with reduced Ejection Fraction (HFrEF) is still a major cause of mortality and morbidity all over the world. This study uses bibliometric analysis to trace global publication trends and evaluate the scientific production, citation impact, contributions of authors, institutions and countries, collaboration patterns, and thematic evolution of Guideline-Directed Medical Therapy (GDMT) research in patients with HFrEF. We analyzed the data using Bibliometrix (R package) and VOSviewer v.16.21 to map collaboration networks, citation patterns, and emerging research themes. The analysis indicated a significant increase in academic interest after 2021, with the principal areas of focus being heart failure (HF), HFrEF, chronic kidney disease, Sacubitril/Valsartan, diabetes, and ivabradine; this trend shows that the emphasis is on existing treatments for HF and its major comorbidities. Researchers identified 693 peer-reviewed academic sources authored by 20,686 people. McMurray JJV of the Glasgow had the highest h-index, the most citations, and the most publications. Most top authors in GDMT and HFrEF were affiliated with institutions in the United States and Europe. The United States had the greatest research productivity. Although the United States produced the most research, the European countries showed comparatively higher levels of international collaboration. The European Journal of Heart Failure was the most influential journal, having the highest h-index (59) and highest total citation score (11,795). The results show that research into GDMT-HFrEF is highly concentrated in the major cardiovascular and heart failure journals . The thematic analysis of Authors keywords shows that in 2021 heart failure and HFrEF were still the main topics. Between 2023 and 2024, Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors and mineralocorticoid receptor antagonists became important themes, showing a move towards modern GDMT. By 2025 the subjects of the research had become more diverse and now included HFrEF, SGLT2 inhibitors, Dapagliflozin, pharmacotherapy and other heart failure phenotypes. The results show that research into GDMT-HFrEF is increasingly multidisciplinary and involves greater international cooperation, especially between the United States and Europe. Future studies are expected to concentrate on SGLT2 inhibitors such as dapagliflozin; combination therapies; drug optimization; personalized care; better implementation strategies; and team-based care models.

  • Open Access

    Tuberculosis in Sudan: Epidemiology, diagnosis, and management

    by Taha H. Musa, Hamdan M. Hamdan, Tauseef Ahmad, Riad M. Abdelrahman, Hussein Hamid, Idriss H. Musa, Hassan H. Musa

  • Open Access

    Bibliometric Analysis of Malaria Research in Sudan Published in Scopus Database: Trends and Focus Areas (1956–2024)

    by Riad Mohammed Abdelrahman, Taha Hussein Musa, Sahar Ibrahim Gasmallah, Eltieb Omer Ahmed, Mohammed Jalal

    Background: Malaria, a life-threatening disease, remains a major public health challenge, particularly in Sudan, where it causes significant morbidity and mortality. This review aimed to comprehensively review and explore malaria research in Sudan in the Scopus database and identify cited articles from 1956 to 2024. Methods: A bibliometric and thematic analysis was conducted to explore research on malaria in Sudan. On May 18, 2025, we searched the Scopus database for documents (reviews OR articles) published between 1956 and 2024, using a Boolean search strategy with title-based terms. The aim was to gain comprehensive insights into the growth of malaria research in Sudan, identify key contributions from authors, countries, and institutions, and highlight emerging research topics. Data were analyzed using VOS viewer (version 1.6.6) and the Biblioshiny tool. Results: A total of 252 documents on malaria in Sudan were analyzed, showing a steady publication trend from 1978 to 2022, with a peak in 2004 (17 documents). Citation impact peaked in 2014 (3.6 citations/article) and declined in 2023. Sudan was the leading contributor (138 articles, 55%), with Adam I. from the University of Khartoum as the most prolific author (90 publications, h-index 26). “Malaria Journal” was the most active journal among 105 journals (36 articles, JIF 2.4). “Malaria,” “Sudan,” and “Plasmodium falciparum” were the most explored keywords by authors. Thematic mapping indicated that the emerging themes focused on “thrombocytopenia,” “Anopheles stephensi,” and “antibodies. Keyword analysis did not highlight “ACT-resistant malaria” as an emerging or high-centrality topic. Conclusion: National and international efforts are needed for restarting malaria control in Sudan. Our findings provide an overview of the global status and potential trends of malaria in Sudan. This can assist in exploring the knowledge structure and offers insights for future research on malaria in Sudan.

  • Open Access

    Pharmacovigilance Research: A Bibliometric Performance and Science Mapping Analysis Using the Scopus Database

    by Kannan O. Ahmed, Alka Ahuja, Taha Hussein Musa, Iman Elmahdi Mohamed, Riad Mohammed Abdelrahman, Lukman O. Afolabi, Lovel Fornah

    Background: Pharmacovigilance (PV) is essential for drug safety, but its global development, thematic evolution trends, and collaborative networks are not yet fully mapped. Methods: A bibliometric analysis of Scopus-indexed articles and reviews published between 1960 and 2024 was carried out. Metadata was analyzed using VOSviewer 1.6.20 and the Bibliometrix R package to assess publication trends, influential authors, institutions, countries, co-authorship networks, keyword co-occurrence patterns, and thematic evolution. Multiple Correspondence Analysis and Walktrap clustering were used to map the conceptual structure. Results: A total of 8624 documents were included in the study. Global PV output has increased markedly in the last two decades, with China, the United States, India, and France leading in productivity. Co-authorship networks revealed moderate international collaboration, with emerging economies making a notable contribution. Keyword co-occurrence clusters highlighted major themes, such as adverse drug reactions, PV systems, oncology-related drug safety, and COVID-19 vaccine surveillance. Thematic mapping indicated a shift from foundational ADR reporting to advanced analytical and technology-supported PV methods. Conclusion: PV research is expanding worldwide, with increasing contributions from both high- and middle-income regions. The field demonstrates growing thematic diversification, particularly in oncology and infectious disease PV. Strengthening international collaborations, expanding PV capacity in underrepresented regions, and integrating advanced data analytics are key priorities for future research and policy development.


  • Adverse effects of GLP-1 receptor agonists: Clinical Implications, regulatory perspectives, and future directions

    by Riad Mohammed Abdelrahman, Taha Hussein Musa, Ismail Adam Arbab, Eltieb Omer Ahmed, Sahar Ibrahim Gasmallah, Mohammed Jalal, Chiamaka Linda Mgbechidinma, Wafaa Ramadan Ahmed


  • Open Access

    Mapping Global Research on Adverse Effects of GLP-1 Receptor Agonists (2006-2025): A Scopus-Based Bibliometric and Thematic Analysis

    by Riad Mohammed Abdelrahman, Taha Hussein Musa, Ismail Adam Arbab, Eltieb Omer Ahmed, Sahar Ibrahim Gasmallah, Mohammed Jalal, Wafaa Ramadan Ahmed, Khalid Hamid Fadul

    Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used for managing type 2 diabetes and obesity. As their clinical applications expand, interest in their safety and adverse effects has grown. This study provides a comprehensive bibliometric analysis of global research trends, collaboration patterns, and thematic evolution on GLP-1RA-related adverse effects from 2006 to 2025. This study is a bibliometric analysis. Data were extracted from the Scopus database and analyzed using Bibliometrix (R package) and VOS viewer. Indicators assessed included publication and citation metrics, institutional productivity, and keyword co-occurrence and mapping. Correlations were evaluated using Pearson and Spearman tests, and the Durbin–Watson statistic was applied to assess the independence of residuals. A total of 1075 articles published in 389 journals were identified, authored by 6068 researchers across 85 countries. The annual growth rate was 32.06%, with no single-author papers and 34.23% international co-authorship, indicating strong global collaboration. The United States (30.5%), the United Kingdom (10.6%), and Denmark (7.8%) led in publication output and total citations. Institutional analysis identified Novo Nordisk A/S (60 papers, 11 207 citations) and Eli Lilly & Co. (45 papers, 9948 citations) as the most influential contributors. Diabetes, Obesity and Metabolism published the most articles (n = 106), followed by Diabetes Care and The Lancet Diabetes & Endocrinology. Significant correlations were found between article count and h-index ( r = .677, P < .001) and total citations ( r = .779, P < .001). Keyword analysis revealed 2 main thematic clusters-one pharmacological (drug safety, efficacy, liraglutide, semaglutide) and 1 clinical (human, male, female, adult)—with an emerging focus on population-specific safety since 2021. Research on GLP-1RA-related adverse effects has expanded rapidly, shaped by strong international collaboration and industry-academic partnerships. Future efforts should prioritize balanced global participation, real-world safety data, and mechanistic insights to inform clinical practice and pharmacovigilance.


  • Open Access

    Global Medicines Regulation in Pregnancy and Lactation: Addressing Emerging Therapies, Safety, and Access Inequalities

    by Riad Mohammed Abdelrahman, Khalid Hamid Fadul, Wafaa Ramadan Ahmed, Sahar Ibrahim Gasmallah, Eltieb Omer Ahmed, Ala Gamaleldin Khalifa, Mohsen Hussein Suliman, Ismail Adam Arbab, Taha Hussein Musa, Mohammed Jalal

    Safe medication use during pregnancy and lactation is fundamental to protecting maternal and neonatal health. However, global variability in regulatory frameworks, pharmacovigilance systems, and access to therapies presents major challenges-particularly for emerging treatments such as biologics, GLP-1 receptor agonists, and novel small molecules. This review aimed to synthesize international regulatory frameworks, evaluate safety monitoring practices, and explore disparities in access to medicines for pregnant and lactating populations. A narrative review was conducted using PubMed, Embase, Scopus, Web of Science, and regulatory agency websites (FDA, EMA, Health Canada, MHLW Japan, WHO), supplemented by pharmacovigilance databases (FAERS, VigiBase, EudraVigilance). Publications in English from 2000-2025 addressing regulatory policies, safety monitoring, or access inequalities were included. Extracted data were analyzed to identify global trends, gaps, and best practices in maternal-fetal pharmacotherapy. High-income countries demonstrate mature systems, including the FDA Pregnancy and Lactation Labeling Rule, EMA risk management plans, and comprehensive pharmacovigilance infrastructures. In contrast, low- and middle-income countries (LMICs) often face fragmented regulations, limited monitoring capacity, and restricted access to innovative therapies. Global initiatives such as the World Health Organization (WHO) guidelines, the International Council for Harmonization (ICH) E11(R1) guideline, and TransCelerate programs promote harmonization, yet substantial gaps remain. Active and passive surveillance mechanisms, pregnancy registries, and real-world data enhance safety assessment for emerging therapies, while access inequalities persist due to regulatory delays, cost, and sociocultural barriers. Despite meaningful advances in high-resource settings, LMICs continue to experience major challenges in ensuring safe and equitable access to medicines. Strengthening evidence-based, harmonized regulatory frameworks, expanding pharmacovigilance coverage, and integrating real-world evidence are essential to safeguarding maternal and neonatal health. Coordinated global collaboration is imperative to achieve equitable access to innovative therapies worldwide.

  • Open Access

    Real-world evaluation of cinacalcet on hard outcomes in hemodialysis patients in Saudi Arabia

    by Riad Mohammed Abdelrahman, Azmi Mohamed Ali Abdallah, Ayaz Ahmed Ahmed, Taha Hussien Musa, Ismail Adam Arbab, Eltieb Omer Abuelgasim, Mohammed Jalal, Kannan O. Ahmed, Yousif Amin Hassan, Zainab Altrefe, et al.

    Background: Chronic Kidney Disease (CKD) complications, like cardiovascular complications, are one of the leading causes of mortality. Managing the biochemical profile is essential in slowing the progression of CKD and its associated consequences. This study aimed to assess the effect of cinacalcet add-on therapy on clinical outcomes in patients with End-Stage Renal Disease (ESRD) on Hemodialysis (HD) who developed Secondary Hyperparathyroidism and are receiving hemodialysis. Method: A mixed retrospective-prospective cohort multicenter study was conducted in three hospitals in Saudi Arabia between December 1st, 2019, and January 31st, 2021. Results: One hundred and seventy-four subjects were analyzed; the incidence of the cardiovascular events and the first cardiovascular events in patients on cinacalcet was significantly decreased compared to the patients on the conventional therapy ( p = 0.02 & 0.005, respectively ). The incidence of coronary artery diseases was significantly decreased by 61% in the patients on cinacalcet ( HR = 0.39 , p = 0.04). Patients on Cinacalcet were 69% less in all-cause first hospitalization hazard ratio; HR = 0.31 , 95% CI: 0.16–0.63 , p = 0.001. There was no significant reduction in the risk of all-cause and cardiovascular mortality in the patients on Cinacalcet ( p = 0.06 & 0.12, respectively ), but patients with Hypertension and “Diabetes Mellitus & Hypertension” etiology had a lower mortality HR (Hypertension: HR = 0.46 , 95% CI = 0.21-1.00 , p = 0.05; “Diabetes Mellitus & Hypertension”: HR = 0.42 , 95% CI = 0.2-1.00 , p = 0.04). There was no significant difference in the frequency of incidence of bone fractures between the two groups ( p = 0.26). Conclusion: Cinacalcet is superior in decreasing the frequency of cardiovascular events. However, it is not effective in reducing the risk of all-cause and cardiovascular mortality, except in patients with “Hypertension” and “Diabetes Mellitus & Hypertension” etiology, and it might offer a somewhat protective trend in males and older patients. Clinical trial number: Not applicable.


  • Global trends and focuses of GLP-1RA in obesity: A bibliometric analysis and visualization from 2014 to 2024

    by Riad Mohammed Abdelrahman, Suleiman I. Sharif, Taha Hussein Musa, Hassan Hussein Musa, Ismail Adam Arbab, Mohsen Hussein Suleiman, Khalid Ahmed Mohammed, Sahar Ibrahim Gismallah, Chiamaka Linda Mgbechidinma, Mohammed Jalal, et al.


  • Open Access

    Etiology, biochemical profile, and medications associated with secondary hyperparathyroidism in chronic kidney disease patients in Saudi Arabia

    by Riad M. Abdelrahman, Azmi M. Abdallah, Taha H. Musa, Zainab A. Altrefe, Huda B. Ahmed, Eltieb O. Ahmed

    Secondary hyperparathyroidism in chronic kidney disease (CKD) patients is a challenge for nephrologists, and its diagnosis and treatment take a huge effort from healthcare providers due to its associated clinical complications. This study aims to evaluate the prevalence, biochemical profile, and drugs associated with CKD. A retrospective cohort study was conducted for the period of December 2019 to January 2021 for 130 patients on dialysis in Al-Mana Hospitals-Kingdom of Saudi Arabia (KSA). Data were compared for the intact parathyroid hormone (iPTH) ranges (600 pg/ml). Mean age was 64.37 ± 10.83 years. Diabetic nephropathy was dominant (n = 109.84%). The mean iPTH, calcium, and phosphorus levels were 631.42 ± 468.41 pg/ml, 8.60 ± 0.76 mg/dl, and 5.30 ± 1.52 mg/dl, respectively. The prevalence of patients within the Kidney Disease Improving Global Outcomes (KDIGO)-acceptable iPTH target was 65%. A negative non-significant correlation of calcium and a positive significant correlation of phosphorus with iPTH levels were observed (r = −0.6, p = 0.28 and r = 0.9, p = 0.04, respectively). These findings can be used to improve compliance with KDIGO guidelines for CKD management. Regular monitoring and individualized care are essential to maintain mineral balance and improve outcomes, especially in diabetic and older patients.